Celgene International Sarl CELG today announced data from multiple phase III studies evaluating the benefit/risk profile of REVLIMID were presented during the International Myeloma Workshop in Paris, France.
The updated results were from four phase III studies of REVLIMID (lenalidomide), either as continuous therapy following high-dose melphalan and autologous stem cell therapy, as continuous therapy following induction
with melphalan, prednisone and lenalidomide in patients with newly diagnosed multiple myeloma, or as therapy with lenalidomide plus dexamethasone as induction followed by continuous lenalidomide therapy in patients with smoldering multiple myeloma. Also presented was a retrospective safety analysis of 11 Celgene-sponsored trials evaluating lenalidomide plus dexamethasone in relapsed/refractory multiple myeloma patients.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in